Skip to main content
. 2021 Nov 30;10(23):e021873. doi: 10.1161/JAHA.121.021873

Table 1.

Demographic, Clinical, and Echocardiographic Parameters, Overall and According to AT/ET ≤0.35 and >0.35

Variable All (N=353) AT/ET ≤0.35 (n=183) AT/ET >0.35 (n=170) Overall P value
Demographic and clinical characteristics
Age, y 79 (71 to 85) 77 (68 to 84) 78 (70 to 84) 0.665
Female sex, n (%) 163 (46) 80 (44) 83 (49) 0.393
Body surface area, m² 1.86 (1.72 to 2.00) 1.87 (1.69 to 2.00) 1.86 (1.73 to 2.00) 0.628
BMI, kg/m² 27.1 (23.9 to 31.2) 27.0 (23.9 to 30.8) 27.3 (23.9 to 32.1) 0.274
SBP, mm Hg 140 (126 to 151) 140 (130 to 156) 138 (120 to 150) 0.002
DBP, mm Hg 73 (65 to 80) 72 (64 to 80) 75 (67 to 80) 0.536
Heart rate, bpm 75 (66 to 84) 75 (66 to 84) 74 (66 to 84) 0.965
Hypertension, n (%) 263 (74.5) 149 (81) 114 (67) 0.003
Diabetes, n (%) 107 (30) 59 (32) 48 (28) 0.483
Documented CAD, n (%) 124 (35) 69 (38) 55 (32) 0.347
History of AF, n (%) 86 (24) 50 (27) 36 (21) 0.222
Use of β blockers, n (%) 139 (39) 76 (41) 63 (37) 0.453
Charlson comorbidity index 1 (0 to 3) 1 (0 to 3) 1 (0 to 3) 0.573
NYHA functional class I, n (%) 147 (42) 84 (46) 63 (37) 0.115
Echocardiographic parameters
Aortic valve
AVA, cm² 0.76 (0.63 to 0.87) 0.77 (0.67 to 0.90) 0.74 (0.58 to 0.85) 0.005
AVAi, cm²/m² 0.41 (0.34 to 0.47) 0.43 (0.37 to 0.48) 0.39 (0.32 to 0.45) <0.001
Peak aortic jet velocity, m/s 4.40 (4.18 to 4.80) 4.35 (4.11 to 4.60) 4.50 (4.20 to 5.00) 0.001
Mean pressure gradient, mm Hg 49 (44 to 58) 46 (42 to 52) 53 (45 to 64) <0.001
Dimensionless index 0.20 (0.17 to 0.24) 0.22 (0.19 to 0.24) 0.19 (0.16 to 0.22) <0.001
Acceleration time, ms 107 (93 to 122) 96 (83 to 108) 120 (109 to 130) <0.001
Ejection time, ms 305 (283 to 332) 304 (277 to 332) 306 (287 to 333) 0.647
AT/ET 0.35 (0.32 to 0.39) 0.32 (0.30 to 0.34) 0.39 (0.37 to 0.42) By design
Other parameters
AF during TTE, n (%) 31 (9) 19 (10) 12 (7) 0.361
LVEDD, mm 48 (43 to 52) 47 (43 to 52) 48 (43 to 54) 0.361
LVESD, mm 29 (26 to 34) 29 (25.5 to 33) 30 (26 to 35) 0.114
LV‐SV, mL 80 (66 to 93) 80 (68 to 91) 79 (65 to 95) 0.508
LV‐SVi, mL/m² 43 (37 to 50) 44 (39 to 50) 42 (35 to 49) 0.082
LV ejection fraction, % 63 (60 to 68) 64 (60 to 68.5) 63 (59 to 66) 0.020
Flow rate, mL/s 260 (221 to 311) 262 (226 to 312) 256 (212 to 302) 0.182
GLS, % (N=244) −14.9 (−17.2 to −12) −15.5 (−18 to −12.9) −14.5 (−16.6 to −11) 0.007
RWT 0.51 (0.43 to 0.61) 0.50 (0.42 to 0.59) 0.52 (0.44 to 0.63) 0.062
LVMi, g/m² 120 (99.2 to 146) 117 (95.4 to 138) 128 (104 to 153) 0.004
LAVi, mL/m² 41 (33 to 52) 41 (32 to 51) 43 (34 to 54) 0.140
E/A ratio 0.77 (0.63 to 1.01) 0.77 (0.65 to 1.01) 0.77 (0.63 to 1.01) 0.662
E/e' ratio 8.94 (6.50 to 12.9) 9.00 (7.00 to 12.4) 8.50 (5.92 to 13.1) 0.237
PAPs, mm Hg (N=266) 35 (29 to 42) 35 (29 to 41) 34.5 (30 to 42) 0.940
TAPSE 22 (19 to 25) 22 (19 to 26) 21 (18 to 25) 0.129

Continuous variables are presented as median (25th to 75th percentile). Categorical variables are presented as absolute numbers and frequency. A indicates mitral A wave velocity; AF, atrial fibrillation; AT/ET, ratio of acceleration time/ejection time; AVA, aortic valve area; AVAi, AVA indexed to body surface area; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; DBP, diastolic blood pressure; E, mitral E wave velocity; e', early diastolic mitral annular velocity; GLS, global longitudinal strain; LAVi, left atrial volume indexed to body surface area; LV, left ventricular; LVEDD, LV end‐diastolic diameter; LVESD, LV end‐systolic diameter; LVMi, LV mass indexed to body surface area; NYHA, New York Heart Association; PAPs, systolic pulmonary artery pressure; RWT, relative wall thickness; SBP, systolic blood pressure; SV, stroke volume; SVi, SV indexed to body surface area; TAPSE, tricuspid annular plane systolic excursion; and TTE, transthoracic echocardiography.